- I've long maintained that pharmaceutical companies are running a racket. This is the most blatant case I've seen yet. Martin Shkreli is a former New York hedge fund manager who decided to get into the prescription drug business. He's now the CEO of Turing Pharmaceuticals. Vice News reports, Turing recently acquired the rights to the anti parasitic drug Daraprim. It's used to prevent malaria, and infections that can result from cancer and aids The company almost immediately raised the price of the drug from $13.50 a pill to $750.00. There's been a backlash, and Shkreli is unrepentant. His tweets on the subject are arrogant, to say the least.